LIPT1

Across TCGA pan-cancer cohorts, LIPT1 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LIPT1 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LIPT1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LIPT1 expression acts as an unfavorable survival marker.

CCRCC and LUAD are the cancer types where LIPT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.418	0.788	.019	20	view →
LUAD	OS	Median	II,III,IV	0.782	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

LIPT1–CCRCC (DFS)

Open the CCRCC breakdown →